Research Progress and Prospects in Targeted Therapy for Colorectal Cancer
10.3969/j.issn.1008-7125.2019.11.008
- Author:
Siyuan PAN
1
Author Information
1. Division of Gastroenterology and Hepatology, School of Medicine, Shanghai Jiao Tong University
- Publication Type:Journal Article
- Keywords:
Colorectal Neoplasms;
Drug Resistance, Neoplasm;
Epidermal Growth Factor Receptor;
Human Epidermal Growth Factor Receptor 2;
Molecular Targeted Therapy;
Programmed Cell Death 1 Receptor;
Vascular Endothelial Growth Factor
- From:
Chinese Journal of Gastroenterology
2019;24(11):678-682
- CountryChina
- Language:Chinese
-
Abstract:
Targeted drug combined with chemotherapy have become the trend in treatment of advanced colorectal cancer, one of the most common cancers worldwide. To date, nearly ten targeted drugs have been approved for clinical use, helping to extend patients' lifetime by months or even years. Meanwhile, with the exploration in etiology and molecular pathogenesis, new targeted drugs come forth continuously. However, problems remain in various aspects, such as ways to dealing with drug resistance, individualized drug choice and treatment decisions. This review article described the achievements and challenges in targeted therapy for colorectal cancer.
